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Summary Interleukin 10 (IL-10) is an immunosuppressive factor and has been detected in tumour cell cultures of renal cell carcinoma and of
malignant melanoma. IL-10 has been described as a cytokine of the Th2 response; it is able to suppress antigen-presenting cells (APCs) and
may lead to down-regulation of HLA class I and II molecules on dendritic cells and to anergy of T-lymphocytes. We evaluated pretreatment
serum levels of soluble IL-10 and various clinical parameters to determine their prognostic value in 80 advanced renal cell carcinoma patients
seen at our institution between May 1990 and April 1996. For statistical evaluation we used both univariate and multivariate Cox proportional
hazards models. An elevated pretreatment serum level of IL-10 was a statistically independent predictor of unfavourable outcome
(P < 0.0028), in addition to the well-known clinical and biochemical risk factors. These data support risk stratification for future therapeutic
trials and identify a predictor which needs to be validated in prospective studies and may potentially influence decision making in palliative
management of patients with metastatic renal cell carcinoma. These data also suggest a potential role of IL-10 in the development of
advanced renal cell carcinoma and in the future design of therapeutic strategies. 
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Table 1 Patient characteristics
IL-10 ≤ 1 pg ml–1 IL-10 > 1 pg ml–1
Variable n na n
Patients 80 59 21
Sex
Male 60 44 16
Female 20 15 5
Age (years)
Mean 57 56 57
Range 32–74 37–72 32–74
Metastases
Lung 59 43 16
Bone 23 17 6
Liver 20 13 7
Brain 11 8 3
Tumour sites
1 28 24 4
> 1 52 35 17
aSerum IL-10 levels were assayed prior to systemic therapy.
Table 2 Impact of pretreatment serum IL-10 levels and clinical factors on
patient survival in 80 consecutive patients with advanced renal cell
carcinoma by univariate analysis
Variable Categories compareda P-value
Clinical factors
Sex Female vs. male 0.89
Age (years) < 60 vs. ≥ 60 0.155
Time between diagnosis > 12 vs. ≤ 12 0.16
and progression
(months)
Haemoglobin (g dl–1) ≥ 10 vs. < 10 0.0000
ESR (mm h–1) < 50 vs. ≥ 50 0.0004
LDH (U l–1) < 240 vs. ≥ 240 0.016
Lung metastases Present vs. absent 0.86
Bone metastases Absent vs. present 0.18
Liver metastases Absent vs. present 0.92
Brain metastases Absent vs. present 0.12
Local relapse Absent vs. present 0.35
IL-10 (pg ml–1) ≤ 1 vs. > 1 0.0028
aFor each variable, the prognostic significance of the first category listed
was assessed by comparing that category with the reference category
(the second category listed).
Months
P =0.0028


















< 1 pg ml–1(n=59)
> 1 pg ml–1(n=21)
Figure 1 Serum IL-10 and survival in 80 patients with metastatic renal cell
carcinoma. Survival curves (Kaplan–Meier estimate) of patients with either
low (≤ 1 pg ml–1) or elevated (> 1 pg ml–1) serum levels of IL-10. P-value was
determined by log rank test. Tick marks represent patients for whom data
were censored.
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Univariate analysis of pretreatment variables and
survival
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Table 3 Hazard ratios associated with pretreatment predictors of overall survival in a multivariate analysis of 80
consecutive patients with metastatic renal cell carcinoma, using Cox proportional hazards models
Hazard ratio
Variable Categories compareda (95% confidence interval) P-valueb
Clinical factors
LDH (U l–1) < 240 vs. ≥ 240 0.48 (0.26–0.89) 0.0233
ESR (mm h–1) < 50 vs. ≥ 50 0.31 (0.15–0.65) 0.049
Haemoglobin (g dl–1) ≥ 10 vs. < 10 0.20 (0.09–0.45) 0.0005
Interleukin 10 (pg ml–1) ≤ 1 vs. > 1 0.50 (0.26–0.89) 0.0226
aFor each variable, the prognostic significance of the first category listed was assessed by comparing that category
with the reference category (the second category listed). bFor the comparison of the hazard ratio shown with a hazard
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